KMC Speciality Share Price Target 2026–2030 and What Drives It

KMC Speciality Hospitals share price today

KMC Speciality Hospitals is one of the smaller listed healthcare businesses in India and one of the more profitable ones. It runs a multi-specialty hospital in Trichy, it belongs to the Kauvery Hospitals group, and on the reported numbers it earns a return on capital employed of 26%. The investment tension is that a single-city hospital operator with a ₹2,226 crore market capitalisation is being priced at close to forty times trailing earnings, which is the sort of multiple usually reserved for businesses with a longer runway of new locations behind them.

At the 10 September 2026 research cut-off, Screener showed a price of ₹136, market capitalisation of about ₹2,226 crore, trailing EPS of ₹3.42 and book value per share of ₹12.9. That works out to roughly 39.8 times trailing earnings and 10.6 times book. The 52-week range runs from ₹65 to ₹148, so the stock sits about 8.1% below its high and a little over twice its low.

One practical caveat before anything else. KMC Speciality is listed on the BSE only, with no NSE line, and the market-data feed we normally use for the live quote box is stale for this scrip code. The live quote panel on this page is therefore switched off, and every price figure quoted below, including the 52-week range, comes from Screener’s reading on 10 September 2026 rather than from a streaming feed. Verify the current price with your broker before treating any number here as today’s market level.

What the KMC Speciality share price reflects

The KMC Speciality share price has compressed several years of return into a short window. Screener’s share-price CAGR series reads 34% over ten years, 19% over five years and 16% over three years, but 110% over the last one year. A three-year rate of 16% alongside a one-year move of 110% tells you that the market changed its mind about this company recently rather than gradually.

The earnings record explains part of that. Trailing-twelve-month sales growth is 35% and trailing profit growth is 138%, against a three-year profit CAGR of only 20%. In other words, the most recent twelve months are far better than the three years that preceded them. Whether that is a step change in the business or a favourable comparison against a weak FY25 is the single most important question on this stock, and the annual series alone cannot settle it.

What KMC Speciality Hospitals actually operates

The company was incorporated in 1982 and is described in its filings as running, operating and maintaining a multi-specialty hospital in Trichy, with medical and healthcare services as its primary activity. It sits inside the Kauvery Hospitals group, which the company describes as more than 2,250 beds across 12 locations.

Attribute	Detail from the filing record
Incorporated	1982
Principal operation	Multi-specialty hospital in Trichy
Group	Kauvery Hospitals, stated as 2,250+ beds across 12 locations
Listing	BSE only, scrip code 524520
Face value	₹1 per share
Size band	Micro-cap, ₹2,226 crore market capitalisation
Dividend record	No payout in any year of the reported series

That structure matters more than it looks. A regional hospital with a recognisable brand and a referral catchment can hold pricing and occupancy in a way a generic clinic cannot, and the group affiliation supplies clinical depth that a standalone unit of this size would struggle to fund. The flip side is concentration: one city, one primary campus and one local competitive environment carry the whole result.

Twelve years of revenue, margin and profit

The long series is the most persuasive part of the file. Sales were ₹36 crore in FY15. They were ₹306 crore in FY26 and ₹331 crore on a trailing basis. Operating margin widened from 16% to the high twenties over the same stretch, which is the opposite of what usually happens when a small operator scales.

Financial year	Sales (₹ Cr)	Operating margin	Net profit (₹ Cr)	EPS (₹)
FY20	96	22%	12	0.72
FY21	103	23%	13	0.78
FY22	136	28%	24	1.46
FY23	156	27%	27	1.64
FY24	177	27%	30	1.86
FY25	232	25%	21	1.31
FY26	306	29%	47	2.87
TTM	331	30%	56	3.42

FY25 is the row that deserves attention. Sales rose from ₹177 crore to ₹232 crore, a gain of about 31%, yet net profit fell from ₹30 crore to ₹21 crore and EPS dropped from ₹1.86 to ₹1.31. Operating margin slipped only two points, from 27% to 25%, so the fall in profit was larger than the fall in operating performance. FY26 then more than doubled profit to ₹47 crore on a 29% margin. The annual series does not say why FY25 broke the pattern, and anyone relying on the FY26 recovery should read the FY25 and FY26 filings on the company’s investor page before assuming it was a one-year event.

Growth rates: fast sales, lumpier profit

Screener’s compounded growth table is worth reading across all four columns at once, because the columns disagree with each other in an informative way.

Measure	10 years	5 years	3 years	Most recent
Sales growth	22%	24%	25%	35% (TTM)
Profit growth	31%	30%	20%	138% (TTM)
Share price return	34%	19%	16%	110% (1 year)
Return on equity	23%	23%	21%	25% (last year)

Sales growth is remarkably stable: 22%, 24%, 25% across ten, five and three years, then a faster trailing period. Profit growth is not stable at all, because the FY25 dip drags the three-year number down to 20% while the ten-year number stands at 31%. When sales compound steadily and profit does not, the variable to watch is margin and below-the-line cost, not demand.

Returns on capital are the strongest part of the record

Return on capital employed is 26% for the latest year and 24.71% averaged over five years. Return on equity is 24.9%, and Screener’s own long series puts ROE at 23% over both ten and five years. A five-year average in the mid-twenties is a different claim from a single good year, and it is the main reason this business attracts a premium rating at all. If you want the mechanics of why a sustained mid-twenties figure is hard to fake, our guide to return on equity walks through the formula and the ways it can be flattered.

Operating margin supports the same reading. The trailing figure is 28.75% on the snapshot and 30% on the trailing column, against 29% in FY26 and 22% in FY20. Hospitals carry high fixed costs, so margin is largely a function of occupancy and case mix. A margin that has widened by roughly eight points over six years while sales tripled suggests the fixed base is being used harder rather than merely expanded.

The balance sheet: expansion funded partly with debt

The asset side has grown quickly. Total assets went from ₹182 crore at FY23 to ₹332 crore at FY26, an increase of about 82% in three years, while borrowings rose from ₹50 crore to a peak of ₹89 crore in FY25 before easing to ₹84 crore.

Balance-sheet line (₹ Cr)	FY23	FY24	FY25	FY26
Equity capital	16	16	16	16
Reserves	97	127	148	194
Borrowings	50	82	89	84
Total assets	182	264	286	332

Equity capital has not moved in twelve years, so shareholders have not been diluted through this expansion; the growth in net worth is retained profit, from negative reserves of ₹6 crore in FY15 to ₹194 crore in FY26. Debt-to-equity stands at 0.4, which is real leverage but not stress at a 26% return on capital. The relevant test is whether the assets added since FY23 earn the same return as the older base, because a hospital’s new capacity always dilutes returns before it fills. If you are unsure how to read a 0.4 reading in context, our debt-to-equity ratio guide covers what the number does and does not capture.

Note also that borrowings fell in FY26 while assets rose, which is the pattern you would expect if the FY26 profit jump was converting into cash rather than into receivables. That is an inference from two lines, not a cash-flow statement, and it should be confirmed against the actual cash-flow disclosure.

Ownership: a 75% promoter block and a thin institutional float

Holder category	10 September 2026
Promoters	75.00%
Foreign institutional investors	0.02%
Public	24.98%
Promoter shares pledged	0%

Promoter holding sits at the 75% regulatory ceiling with no pledged shares, which removes two of the more common governance worries in a micro-cap. The consequence is a free float of roughly a quarter of the company on a single exchange, so the tradable base is small. Screener shows no separate domestic-institutional line at all, and foreign holding is a rounding error. A stock with almost no institutional ownership can move a long way on modest order flow in either direction, which is part of why the one-year price change is 110% while the three-year CAGR is 16%.

Valuation at the research cut-off

Valuation measure	10 September 2026 reading	Interpretation
Screener price	₹136	Fixed research input, not a live quote
Market capitalisation	₹2,226 Cr	Micro-cap; liquidity and single-site risk both matter
Trailing EPS	₹3.42	Screener TTM basis
Recalculated P/E	About 39.8×	Screener’s reported figure is 39.9×
Book value per share	₹12.9	Implies price-to-book of 10.6×
EV/EBITDA	21.3	Includes the ₹84 crore of borrowings
PEG	1.95	Growth is priced, not given away
Dividend yield	0.00%	The case rests entirely on reinvestment
ROCE / ROE	26.0% / 24.9%	The strongest column in the file

Ten and a half times book is a demanding number in isolation, but it is the arithmetic consequence of a 26% return on capital: a business that earns well above its cost of capital should trade above book, and the multiple compounds with the return. Forty times earnings is the harder figure to defend, because it requires the FY26 and trailing earnings level to be a floor rather than a peak. Our P/E ratio explainer sets out why a trailing multiple computed on an unusually strong twelve months tends to understate the true rating.

For sector context on how a much larger, multi-city hospital operator is valued on the same measures, our Apollo Hospitals share price target research covers the listed benchmark in this industry.

Valuation framework

The scenario model starts with TTM EPS of ₹3.42. For each year it applies EPS_TTM × (1 + growth)^(year − 2026 + 112/365) × exit P/E, then rounds the result to the nearest ₹5. The 112/365 factor represents the fraction of the first forecast year remaining from 10 September to 31 December. The company has paid no dividend in any year of the reported series, so no income component is modelled.

Scenario	Annual EPS growth	Exit P/E	Business interpretation
Bear	10%	22×	The trailing profit surge proves partly cyclical, added capacity fills slowly and a single-city micro-cap de-rates toward the wider market
Base	16%	34×	Sales keep compounding in the low-to-mid twenties, margin holds near 29% and the rating stays a little below today’s
Bull	22%	44×	New capacity absorbs quickly, ROCE stays in the mid-twenties and the market keeps paying a scarcity premium for a high-return regional operator

The bear multiple is deliberately far below the present rating, because a stock that has doubled in a year carries multiple risk before it carries earnings risk. The bull multiple is only modestly above today’s, since assuming both sustained 22% earnings growth and permanent multiple expansion would simply restate the current enthusiasm as a forecast. The general method behind these inputs is set out in our guide on how to value a stock. These are scenarios, not probability-weighted forecasts.

KMC Speciality Hospitals share price target 2026 to 2030

The grid above is generated only from the disclosed trailing EPS, the three growth rates and the three exit multiples in the table. It models nothing else. It does not account for a share issue, an acquisition, a change in the group structure, a large debt-funded expansion, an exceptional item, or a change in the regulatory or reimbursement environment for hospitals. It also assumes the trailing EPS of ₹3.42 is a fair starting point, which the FY25 dip is a reason to test rather than assume. Re-run the inputs after each new set of published results.

Risks that can break the thesis

The first risk is geographic concentration. The revenue base is one city. A new competing hospital in the Trichy catchment, the loss of a senior clinical team, or a local demand shock would show up in the numbers with no other region to absorb it.

The second is the starting multiple. At roughly 39.8 times trailing earnings and 10.6 times book, a great deal of execution is already in the price. Earnings can grow at a respectable rate and the shares can still return little if the rating normalises, and the one-year price move of 110% means the rating has already expanded a long way.

The third is the durability of the trailing profit. The trailing figure of ₹56 crore sits against ₹21 crore in FY25 and ₹30 crore in FY24. Trailing profit growth of 138% is not a rate that continues, and the model above already moderates it heavily. If FY25 rather than FY26 turns out to be the representative year, the entire EPS base is wrong.

Fourth is capital intensity, and specifically how the next round of it gets paid for. The assets added since FY23 have not yet been through a full year at whatever occupancy they were built for, so the return on that capital is still unproven. If further expansion is debt-funded while profit is flat, ROCE falls from 26% toward ordinary levels and the premium rating loses the single argument that currently supports it. The question to follow is how any further build is financed, not merely whether it is announced.

Finally, liquidity. A BSE-only listing with a 75% promoter block and effectively no institutional holding makes both entry and exit harder than the headline market capitalisation suggests. On a float this thin, position size decides what is workable at least as much as valuation does.

What would change the reading

Two questions sit above the quarter-to-quarter detail, and the scorecard below deliberately leaves them out because neither fits in a table row.

The first is whether profit growth converges on sales growth. Sales have compounded inside a narrow band — 22%, 24% and 25% over ten, five and three years — while profit swung from minus 30% in FY25 to plus 124% in FY26. A company whose profit line tracks its sales line is a different investment from one whose profit line is the residual of costs it has never explained in public. Convergence over the next two years would establish the FY26 level as a base worth capitalising; a second unexplained divergence would take that away and, with it, the right to use trailing EPS as the model’s starting point at all.

The second is what time does to the rating, which is a slower process than the de-rating described in the risks above. The bull case does not need the multiple to expand, only to hold. If it stays near forty while earnings growth settles into the mid-teens, the arithmetic resolves quietly: several years in which the business performs and the shares do not, because the price is working off a rating set against a 138% trailing profit increase. The mirror image deserves the same attention. A de-rating toward the bear multiple with earnings intact would make this a materially better entry than ₹136 is, and that is the version of the next two years worth having a plan for.

A monitoring scorecard for future results

The rows below are the disclosures that would actually settle the argument, none of which the annual series on this page contains.

Question	Constructive evidence	Warning sign
Does the company disclose operating metrics?	Occupancy, bed count or average revenue per occupied bed appearing in the quarterly release or investor presentation	Revenue and profit reported with no volume or pricing detail behind them
What is capex doing relative to sales?	Capex falling as a share of sales once the capacity added since FY23 is commissioned and filling	A second large capex cycle starting before the first one has filled
Is profit converting into cash?	Receivable days flat or falling while sales grow, and operating cash flow tracking reported profit	Receivables growing faster than sales, which would undercut the cash inference drawn from the FY26 borrowings line
Has management dated the fill?	A stated timeline for the added capacity to reach target occupancy, with results measured against it	No timeline offered, leaving nothing to hold the ROCE trajectory against
Are group dealings disclosed cleanly?	Related-party transactions with the Kauvery group itemised in the notes, and the promoter block steady at 75% with no pledge	Growing or unexplained related-party balances, or a first pledge
Is capital being returned?	A first dividend or a stated payout policy	Continued zero payout alongside falling returns

FAQ

What is the share price target for KMC Speciality Hospitals in 2030?

The scenario grid on this page builds 2030 from trailing EPS of ₹3.42, three annual earnings-growth rates and three exit P/E multiples. It should be read as a range of outcomes under stated assumptions, not as a forecast or a recommendation. A single number for 2030 would imply a precision the inputs do not support.

What is the share price target for KMC Speciality Hospitals in 2026?

The 2026 line covers only the fraction of the year left after the 10 September cut-off, which the model handles with the 112/365 factor described above. It is therefore the least interesting row in the grid: over four months, the multiple matters far more than the growth rate.

What does KMC Speciality Hospitals (India) Limited do?

It runs, operates and maintains a multi-specialty hospital in Trichy, and its primary activity is medical and healthcare services. The company was incorporated in 1982 and forms part of the Kauvery Hospitals group, which spans more than 2,250 beds across 12 locations.

Is KMC Speciality Hospitals listed on the NSE or the BSE?

It is listed on the BSE only, under scrip code 524520, with no NSE line. In practice that means it will not appear in a watchlist, screener or broker search filtered to NSE symbols, and that every price on this page is Screener’s reading from 10 September 2026 for the reason set out at the top.

What is the ROCE of KMC Speciality Hospitals?

Return on capital employed is 26% for the most recent year and 24.71% averaged across five years. Return on equity is 24.9%. The five-year average is the more meaningful of the two figures because it shows the return has been sustained rather than produced by one strong year.

Who are the promoters of KMC Speciality Hospitals?

The promoter group holds 75.00% of the equity, the maximum permitted under public shareholding rules, with none of those shares pledged. The company belongs to the Kauvery Hospitals group. Foreign institutional investors hold 0.02% and the public holds the remaining 24.98%.

Related research

• Caplin Point Labs share price target — another small-cap healthcare name run through the same scenario method
• Abbott India share price target — a healthcare business at the opposite end of the size and liquidity scale
• How to read quarterly results — the method for testing FY25 against FY26 in the filings yourself
• Fundamental analysis of stocks — how the ratios used on this page fit together
• Best stock screener in India — where figures like these are pulled from, and their limits

Sources and methodology

• KMC Speciality Hospitals on Screener.in
• KMC Speciality Hospitals investor disclosures on the Kauvery site
• Kauvery Hospitals group website

Every financial figure in this article was captured on 10 September 2026. Price, the 52-week range, market capitalisation, trailing EPS, book value, the P/E, price-to-book, EV/EBITDA and PEG readings, the return ratios, the twelve-year sales, margin, profit and EPS series, the balance-sheet lines and the shareholding split all come from Screener.in for BSE scrip code 524520. No Yahoo Finance data was used: the feed for this BSE-only code is stale, which is why the live quote panel is switched off rather than showing a price we cannot stand behind. The company description and group details come from the company’s own filing text and its investor page on the Kauvery site.

Analytical judgment begins after those figures. The reading of FY25 as a break in the pattern, the treatment of trailing EPS as a possibly flattered starting point, the choice of 10%, 16% and 22% earnings growth and of 22×, 34× and 44× exit multiples, and the weighting of concentration, liquidity and multiple risk are ours, not the sources’. They are assumptions, and they are stated so you can disagree with them and substitute your own.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. The scenarios are illustrations, not guarantees. Verify current exchange filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.